Systemic lupus erythematosus presenting with Kikuchi-Fujimoto's disease as a long-term sequela of drug-induced hypersensitivity syndrome: A possible role of Epstein-Barr virus reactivation

Dermatology

Volumn 218, Issue 3, 2009, Pages 275-277

  Aota, N ^a   Hirahara, K ^a   Kano, Y ^a   Fukuoka, T ^a   Yamada, A ^a   Shiohara, T ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug induced hypersensitivity syndrome; Epstein Barr virus encoded RNA; Kikuchi Fujimoto's disease

Indexed keywords

CARBAMAZEPINE; COMPLEMENT; CYCLOSPORIN; PREDNISOLONE; VIRUS RNA;

ADD ON THERAPY; ADULT; ARTICLE; CASE REPORT; CERVICAL LYMPHADENOPATHY; DRESS SYNDROME; DRUG ERUPTION; ENCEPHALITIS; EPSTEIN BARR VIRUS; ERYTHEMA; FACE; GENE EXPRESSION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN TISSUE; KIKUCHI FUJIMOTO DISEASE; LYMPH NODE; LYMPH NODE BIOPSY; LYMPHADENITIS; LYMPHADENOPATHY; MALE; NECK; PANCYTOPENIA; PRIORITY JOURNAL; PROTEINURIA; SKIN BIOPSY; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS REACTIVATION;

ADULT; ANTICONVULSANTS; CARBAMAZEPINE; DRUG HYPERSENSITIVITY; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HISTIOCYTIC NECROTIZING LYMPHADENITIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; VIRUS ACTIVATION;

EID: 62049085338     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000187619     Document Type: Article

References (24)

1. Fujimoto Y, Kojima Y, Yamaguchi K: Cervical subacute necrotizing lymphadenitis. Naika 1972;30:920-927.
2. Kikuchi M, Sumiyoshi Y: Histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto's disease). Byori to Rinsho 1994;12:375-378.
3. Suzuki Y, Inagi R, Aono T, Yamanishi K, Shiohara T: Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol 1998;134:1108-1112.
4. Tohyama M, Yahata Y, Yasukawa M, Inagi R, Urano Y, et al: Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch Dermatol 1998;134:1113-1117.
5. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K: The diagnosis of DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007;156:1083-1084.
6. Hara H, Kobayashi M, Yokoyama A, Tochigi M, Matsunaga A, et al: Drug-induced hypersensitivity syndrome due to carbamazepine associated with reactivation of human herpesvirus 7. Dermatology 2005;211:159-161.
7. Tas S, Simonart T: Herpes viruses in patients with drug hypersensitivity syndrome: culprits, cofactors or innocent bystanders? Dermatology 2006;213:273-276.
8. Kano Y, Sakuma K, Shiohara T: Sclerodermoid graft-versus-host disease-like lesions occurring after drug-induced hypersensitivity syndrome. Br J Dermatol 2007;156:1061-1063.
9. Chiou CC, Chung WH, Hung SI, Yang LC, Hong HS: Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection. J Am Acad Dermatol 2006;54:S14-S17.
10. Sekine N, Motokura T, Oki T, Umeda Y, Sasaki N, Hayashi M, Sato H, Fujita T, Kaneko T, Asano Y, Kikuchi K: Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. JAMA 2001;285:1153-1154.
11. Seino Y, Yamauchi M, Hirai C, Okumura A, Kondo K, Yamamoto M, Okazaki Y: A case of fulminant type 1 diabetes associated with mexiletine hypersensitivity syndrome. Diabet Med 2004;21:1156-1157.
12. Sommers LM, Schoene RB: Allopurinol hypersensitivity syndrome associated with pancreatic exocrine abnormalities and newonset diabetes mellitus. Arch Intern Med 2002;162:1190-1192.
13. Hu S, Kuo TT, Hong HS: Lupus lymphadenitis simulating Kikuchi's lymphadenitis in patients with systemic lupus erythematosus: a clinicopathological analysis of six cases and review of the literature. Pathol Int 2003;53:221-226.
14. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB: An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019-3026.
15. Kano Y, Hirahara K, Sakuma K, Shiohara T: Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol 2006;155:301-306.
16. Teo RY, Tay YK, Tan CH, Ng V, Oh DC: Presumed dapsone-induced drug hypersensitivity syndrome causing reversible hypersensitivity myocarditis and thyrotoxicosis. Ann Acad Med Singapore 2006;35:833-834.
17. James JA, Neas BR, Moser KL, Hall T, Bruner GR, Sestak AL, Harley JB: Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001;44:1122-1126.
18. Vardolini R, Bugatti L, Giangiacomi M, Nicolini M, Filosa G, Cerio R: Systemic lupus erythematosus induced by Epstein-Barr virus infection. Br J Dermatol 2002;146:877-881.
19. Dror Y, Blachar Y, Cohen P, Livni N, Rosenmann E, Ashkenazi A: Systemic lupus erythematosus associated with acute Epstein-Barr virus infection. Am J Kidney Dis 1998;32:825-828.
20. Huggins ML, Todd I, Powell RJ: Reactivation of Epstein-Barr virus in patients with systemic lupus erythematosus. Rheumatol Int 2005;25:183-187.
21. Kang I, Quar T, Nolasco H, Park SH, Hong MS, Crouch J, Pamer EG, Howe JG, Craft J: Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 2004;172:1287-1294.
22. Cohen JI: The biology of Epstein-Barr virus: lessons learned from the virus and the host. Curr Opin Immunol 1999;11:365-370.
23. Williams H, Crawford DH: Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood 2006;107:862-869.
24. Sitiki-Green GL, Edwards RH, Covington MM, Raab-Traub N: Biology of Epstein-Barr virus during infectious mononucleosis. J Infect Dis 2004;189:483-492.